These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase.
    Author: Millot F, Claviez A, Leverger G, Corbaciglu S, Groll AH, Suttorp M.
    Journal: Pediatr Blood Cancer; 2014 Feb; 61(2):355-7. PubMed ID: 24106110.
    Abstract:
    Imatinib can be safely discontinued in adults with chronic myeloid leukemia (CML) where there is a prolonged complete molecular response (CMR). No data are available in the pediatric population. Six children with CML discontinued imatinib by themselves. Only three of them were in CMR but for <2 years. A significant increase in transcript level was observed in all six patients after cessation of imatinib and five patients lost the major molecular response (MMR). Four patients regained the MMR within 3 months. Cessation of imatinib in children is not recommended outside a trial, particularly in patients without prolonged CMR.
    [Abstract] [Full Text] [Related] [New Search]